Ah Receptor Antagonism Represses Head and Neck Tumor Cell Aggressive Phenotype
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The aryl hydrocarbon receptor (AhR) has been shown to play a role in an increasing number of cellular processes. Recent reports have linked the AhR to cell proliferation, cytoskeletal arrangement, and tumor invasiveness in various tumor cell types. The AhR plays a role in the de-repression of the interleukin (IL)6 promoter in certain tumor cell lines, allowing for increased transcriptional activation by cytokines. Here, we show that there is a significant level of constitutive activation of the AhR in cells isolated from patients with head and neck squamous cell carcinoma (HNSCC). Constitutive activation of the AhR in HNSCCs was blocked by antagonist treatment, leading to a reduction in IL6 expression. In addition, the AhR exhibits a high level of expression in HNSCCs than in normal keratinocytes. These findings led to the hypothesis that the basal AhR activity in HNSCCs plays a role in the aggressive phenotype of these tumors and that antagonist treatment could mitigate this phenotype. This study provides evidence that antagonism of the AhR in HNSCC tumor cells, in the absence of exogenous receptor ligands, has a significant effect on tumor cell phenotype. Treatment of these cell lines with the AhR antagonists 6, 2′, 4′-trimethoxyflavone, or the more potent GNF351, decreased migration and invasion of HNSCC cells and prevented benzo[a]pyrene-mediated induction of the chemotherapy efflux protein ABCG2. Thus, an AhR antagonist treatment has been shown to have therapeutic potential in HNSCCs through a reduction in aggressive cell phenotype. Mol Cancer Res; 10(10); 1369–79. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575 · cited 1×
“Matrix metalloproteinases (MMP) are a family of proteinases commonly studied in the context of their secretion by tumor cells for the purpose of degrading extracellular matrix proteins to allow for invasion into neighboring tissue (25, 26).”
The Aryl Hydrocarbon Receptor Complex and the Control of Gene Expression
Beischlag, T. V., Morales, J. L., Hollingshead, B. D., & Perdew, G. H. (2008) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v18.i3.20 · Cited by 727 · cited 1×
“The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that has been largely regarded as a mediator of xenobiotic metabolism for decades (1).”
BackgroundSelf-citationYadav, A., Kumar, B., Datta, J., Teknos, T. N., & Kumar, P. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0271 · Cited by 503
A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors
Andersson, P., McGuire, J., Rubio, C., Gradin, K., Whitelaw, M. L., Pettersson, S., Hanberg, A., & Poellinger, L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152706299 · Cited by 310
Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M. (2007) · The FASEB Journal · doi:10.1096/fj.07-8832com · Cited by 222
Cited by
Aryl hydrocarbon receptor ligands in cancer: friend and foe
Murray, I. A., Patterson, A. D., & Perdew, G. H. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3846 · Cited by 883
Self-citationIndole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation
Hubbard, T. D., Murray, I. A., & Perdew, G. H. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064246 · Cited by 640
Self-citationThe Aryl Hydrocarbon Receptor in Barrier Organ Physiology, Immunology, and Toxicology
Esser, C., & Rannug, A. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009001 · Cited by 501
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Fujiwara, Y., Kato, S., Nesline, M. K., Conroy, J. M., DePietro, P., Pabla, S., & Kurzrock, R. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102461 · Cited by 304
Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target
Safe, S., Lee, S.-O., & Jin, U.-H. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft128 · Cited by 264
Metadata
- Authors
- DiNatale, B. C., Smith, K., John, K., Krishnegowda, G., Amin, S. G., & Perdew, G. H.
- Venue
- Molecular Cancer Research
- Published
- 2012-10-01
- Volume
- 10
- Issue
- 10
- Pages
- 1369-1379
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2144678247
- Cited by
- 71
- References
- 5
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ah Receptor Antagonism Represses Head and Neck Tumor Cell Aggressive Phenotype. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-12-0216
- The paper
- DiNatale, B. C., Smith, K., John, K., Krishnegowda, G., Amin, S. G., & Perdew, G. H. (2012). Ah Receptor Antagonism Represses Head and Neck Tumor Cell Aggressive Phenotype. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-12-0216
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.